A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

  • End date
    Dec 13, 2023
  • participants needed
  • sponsor
    Annexon, Inc.
Updated on 13 March 2021


This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate. The results will be used to guide further development of ANX007 in participants with geographic atrophy. The total duration of participation is expected to be approximately 19 months.

Condition Dry Macular Degeneration, age-related macular degeneration, Macular Degeneration, Geographic Atrophy
Treatment Sham comparator, ANX007
Clinical Study IdentifierNCT04656561
SponsorAnnexon, Inc.
Last Modified on13 March 2021


Yes No Not Sure

Inclusion Criteria

Diagnosis of geographic atrophy of the macula secondary to age-related macular degeneration as determined by the Investigator and confirmed by the Central Reading Center
GA lesion must have the following characteristics as determined by the independent Central Reading Center based on assessment of FAF imaging at screening
Well-demarcated GA with a total area (baseline lesion size) 2.5 mm2 and 17.5 mm2
If GA is multifocal, at least 1 focal lesion must measure 1.25 mm2 with the overall aggregate area of GA as specified above
Presence of hyper autofluorescence, any pattern, in the junctional zone of the GA. Absence of hyper autofluorescence (ie, pattern = none) is exclusionary
The entire GA lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any peripapillary atrophy
Normal luminance best corrected visual acuity (BCVA) of 24 to 83 letters, inclusive, using Early Treatment Diabetic Retinopathy Study (ETDRS) charts (20/25 to 20/320 Snellen equivalent, inclusive)
A female patient is eligible if she is not pregnant or breastfeeding and is a woman of non-childbearing potential or is using a contraceptive method that is highly effective, with a failure rate of <1% during the study intervention period and for at least 30 days after the last dose of study intervention

Exclusion Criteria

Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (eg, plaquenil maculopathy) in either eye
Any evidence of choroidal neovascularization (CNV) in the study eye
Any history of CNV of any cause based on medical history
Evidence of prior or active CNV or related findings (eg, retinal pigment epithelial rips or tears) based on FAF, SD-OCT imaging, intravenous fluorescein angiography (IVFA) and color fundus photo as assessed by the Central Reading Center
Spherical equivalent of -8.00 diopters (D) myopia or higher in the study eye
Uncontrolled glaucoma in the study eye (IOP >25 mmHg despite treatment with antiglaucoma medication) or history of neovascular glaucoma
History of glaucoma filtration surgery, minimally-invasive glaucoma surgery involving an implant, or vitrectomy surgery, or other procedure in the study eye that could affect drug distribution and/or clearance
Any current or prior ocular disease, other than geographic atrophy, that in the opinion of the Investigator could interfere with the conduct of the study including, but not limited to, insufficient pupil dilation, retinal or optic nerve disease, media opacity, or aphakia in the study eye
History of any prior IVT treatment for any indication in the study eye
Any prior treatment for AMD in the study eye (eg, surgical, radiation, thermotherapeutic, or laser intervention), except oral supplements or minerals
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note